Patents by Inventor Jim Dimetrios COLOMVAKOS

Jim Dimetrios COLOMVAKOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
    Publication number: 20230382942
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 30, 2023
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • Crystalline forms of a CD73 inhibitor and uses thereof
    Patent number: 11649261
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: May 16, 2023
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Andrew M. K. Pennell, Eric F. Connor, Stephen Edmund Gottschling, Jim Dimetrios Colomvakos, Mohammed Asadullah Khan
  • CRYSTALLINE FORMS OF A CD73 INHIBITOR AND USES THEREOF
    Publication number: 20210395291
    Abstract: Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The use of such crystalline form of Formula (I) and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: June 16, 2021
    Publication date: December 23, 2021
    Inventors: Andrew M. K. PENNELL, Eric F. CONNOR, Stephen Edmund GOTTSCHLING, Jim Dimetrios COLOMVAKOS, Mohammed Asadullah KHAN